A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer

NCT ID: NCT03281096

Last Updated: 2022-07-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 1000 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-08-29
• Study Completion Date: 2021-03-01

Brief Summary

Experimental studies in animals and observational studies in humans suggest that fusobacterium nucleatum is associates with stages of colorectal neoplasia development, and Berberine Hydrochloride could rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. Whether regular Berberine Hydrochloride use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers is worth to further study.

Detailed Description

The prevalence of colorectal adenomas is high in our country, as is the incidence of colorectal cancer. It is well-known that colorectal adenomas are the precursor of colorectal cancer and that removing them will prevent colorectal cancer. Because most colorectal cancers arise from benign adenomas, adenomas have been used as surrogate end points in prevention trials. Berberine hydrochloride, which is an alkaloid extracted from Rhizoma coptidis, has been traditionally used in Chinese medicine to treat gastrointestinal infections, due to its antimicrobial properties. Previous clinical research and animal studies have demonstrated the anti-tumor action of Berberine hydrochloride. Persons with a history of colorectal cancer might constitute a group at higher risk for adenomas and thus be particularly suitable for a study of the chemopreventive effects of Berberine hydrochloride. Here, a randomized, double-blind, placebo-controlled trial was designed to determine whether the daily use of 300 mg of berberine hydrochloride could decreases the occurrence of new colorectal adenomas among patients with a history of colorectal cancer.

Conditions

Colorectal Adenomas

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Berberine hydrochloride group

Berberine hydrochloride 300mg tablet by mouth, two times per day for 3 years

Group Type: EXPERIMENTAL

Berberine hydrochloride

Intervention Type: DRUG

patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.

Placebo

identical-appearing placebo 300mg tablet by mouth, two times per day for 3 years

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

pill manufactured to mmic Berberine hydrochloride 100mg tablet

Interventions

Berberine hydrochloride

patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.

Intervention Type: DRUG

Placebo

pill manufactured to mmic Berberine hydrochloride 100mg tablet

Intervention Type: DRUG

Other Intervention Names

Berberine hydrochloride tablet ("Sine Tianping"); Placebo (for Berberine hydrochloride)

Eligibility Criteria

Inclusion Criteria

• Patients aged 18-80 years
• Patients who had histologically documented colon or rectal cancer with a low risk of recurrent disease
• Patients with Dukes' stage A or B1 colon or rectal cancer (tumor-node-metastasis [TNM] stage T1 to T2, N0, M0) who had undergone curative resection of the primary tumor were immediately eligible for enrollment
• Patients with Dukes' stage B2 or C (T3 to T4, N0 to N1, M0) colon or rectal cancer who had undergone curative resection of the primary tumor were eligible if they had been free of disease for more than five years after curative surgery
• Eligible participants had to have undergone, after adequate preparation, colonoscopy to the cecum (or small-bowel anastomosis), with removal of all polyps, within four months before study entry
• Patients were eligible if they were in good general health, with an expected survival of at least five years; willing to provide and able to understand informed consent and to cooperate with the study procedures; not currently enrolled in a clinical trial of colon-cancer treatment or other chemoprevention trial; and not pregnant or nursing.

Exclusion Criteria

• Patients who are hypersensitive or intolerant to the drugs
• Patients had familial polyposis
• Patients had invasive cancer other than nonmelanoma skin cancer within 5 years before the intake appointment
• Patients with diabetes mellitus, severe renal disease or cardiovascular disease (defined by a New York Heart Association functional classof III or IV)
• Patients with hypercalcemia or urolithiasis
• Patients had a history of inflammatory bowel disease
• Patients with hemolytic anemia and glucose -6- phosphate dehydrogenase deficiency
• Patients had received immunosuppressive therapy within the previous 6 months
• Patients had clinically obvious narcotic or alcohol dependence during the previous 6 months
• Patients had used NSAIDs including aspirin at any dose on 3 or more days per month during each of the 3 months before enrollment or for a period of 36 days in the previous year; or had a history of stroke, transient ischemic attacks, angina, myocardial infarction, or atherosclerotic peripheral vascular disease
• Pregnant women, women during breast-feeding period, or women with expect pregnancy
• Patients with a history of subtotal gastrectomy or partial bowel resection
• Patients who are not able to cooperate
• Patients with any condition that could be worsened by supplemental Berberine hydrochloride

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Xijing Hospital of Digestive Diseases

OTHER

Sponsor Role: lead

Responsible Party

xiaohua li

Director of colorectal surgery center

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Weizhong Wang, MD,PH.D

Role: PRINCIPAL_INVESTIGATOR

Xijing digestive surgery center

Locations

Xijing Hospital of Digestive Disease

Xi'an, Shaanxi, China

Countries

China

Other Identifiers

XJLL 2016 001

Identifier Type: -

Identifier Source: org_study_id